|
1
|
Saini S, Majid S and Dahiya R: Diet,
microRNAs and prostate cancer. Pharm Res. 27:1014–1026. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun T, Wang Q, Balk S, Brown M, Lee GS and
Kantoff P: The role of microRNA-221 and microRNA-222 in
androgen-independent prostate cancer cell lines. Cancer Res.
69:3356–3363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ota A, Tagawa H, Karnan S, Tsuzuki S,
Karpas A, Kira S, Yoshida Y and Seto M: Identification and
characterization of a novel gene, C13orf25, as a target for
13q31-q32 amplification in malignant lymphoma. Cancer Res.
64:3087–3095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mogilyansky E and Rigoutsos I: The
miR-17/92 cluster: A comprehensive update on its genomics,
genetics, functions and increasingly important and numerous roles
in health and disease. Cell Death Differ. 20:1603–1614. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mu P, Han YC, Betel D, Yao E, Squatrito M,
Ogrodowski P, de Stanchina E, D'Andrea A, Sander C and Ventura A:
Genetic dissection of the miR-17~92 cluster of microRNAs in
Myc-induced B-cell lymphomas. Genes Dev. 23:2806–2811. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Haaften G and Agami R: Tumorigenicity
of the miR-17-92 cluster distilled. Genes Dev. 24:1–4. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Conkrite K, Sundby M, Mukai S, Thomson JM,
Mu D, Hammond SM and MacPherson D: miR-17-92 cooperates with RB
pathway mutations to promote retinoblastoma. Genes Dev.
25:1734–1745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchida A, Ohno S, Wu W, Borjigin N,
Fujita K, Aoki T, Ueda S, Takanashi M and Kuroda M: miR-92 is a key
oncogenic component of the miR-17-92 cluster in colon cancer.
Cancer Sci. 102:2264–2271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Osada H and Takahashi T: let-7 and
miR-17-92: Small-sized major players in lung cancer development.
Cancer Sci. 102:9–17. 2011. View Article : Google Scholar
|
|
14
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pesta M, Klecka J, Kulda V, Topolcan O,
Hora M, Eret V, Ludvikova M, Babjuk M, Novak K, Stolz J, et al:
Importance of miR-20a expression in prostate cancer tissue.
Anticancer Res. 30:3579–3583. 2010.PubMed/NCBI
|
|
16
|
Sikand K, Slane SD and Shukla GC:
Intrinsic expression of host genes and intronic miRNAs in prostate
carcinoma cells. Cancer Cell Int. 9:212009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sylvestre Y, De Guire V, Querido E,
Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G and Chartrand P:
An E2F/miR-20a autoregulatory feedback loop. J Biol Chem.
282:2135–2143. 2007. View Article : Google Scholar
|
|
18
|
Watahiki A and Wang Y, Morris J, Dennis K,
O'Dwyer HM, Gleave M, Gout PW and Wang Y: MicroRNAs associated with
metastatic prostate cancer. PLoS One. 6:e249502011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo F, Kang S, Zhou P, Guo L, Ma L and Hou
J: Maspin expression is regulated by the non-canonical NF-κB
subunit in androgen-insensitive prostate cancer cell lines. Mol
Immunol. 49:8–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu F, Zhou J, Zhou P, Chen W and Guo F:
The ubiquitin ligase CHIP inactivates NF-κB signaling and impairs
the ability of migration and invasion in gastric cancer cells. Int
J Oncol. 46:2096–2106. 2015.PubMed/NCBI
|
|
21
|
Olive V, Li Q and He L: mir-17-92: A
polycistronic oncomir with pleiotropic functions. Immunol Rev.
253:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao C, Srinivasan L, Calado DP, Patterson
HC, Zhang B, Wang J, Henderson JM, Kutok JL and Rajewsky K:
Lymphoproliferative disease and autoimmunity in mice with increased
miR-17-92 expression in lymphocytes. Nat Immunol. 9:405–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong P, Iwasaki M, Somervaille TC, Ficara
F, Carico C, Arnold C, Chen CZ and Cleary ML: The miR-17-92
microRNA polycistron regulates MLL leukemia stem cell potential by
modulating p21 expression. Cancer Res. 70:3833–3842. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nittner D, Lambertz I, Clermont F,
Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F,
Vandesompele J, Dyer MA, et al: Synthetic lethality between Rb, p53
and Dicer or miR-17-92 in retinal progenitors suppresses
retinoblastoma formation. Nat Cell Biol. 14:958–965. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu H, Han C and Wu T: MiR-17-92 cluster
promotes hepatocarcinogenesis. Carcinogenesis. 36:1213–1222. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu H, Han C, Lu D and Wu T: miR-17-92
cluster promotes cholangiocarcinoma growth: Evidence for PTEN as
downstream target and IL-6/Stat3 as upstream activator. Am J
Pathol. 184:2828–2839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y
and Fan D: miR-17-5p promotes proliferation by targeting SOCS6 in
gastric cancer cells. FEBS Lett. 588:2055–2062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park D, Lee SC, Park JW, Cho SY and Kim
HK: Overexpression of miR-17 in gastric cancer is correlated with
proliferation-associated oncogene amplification. Pathol Int.
64:309–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grillari J, Hackl M and Grillari-Voglauer
R: miR-17-92 cluster: Ups and downs in cancer and aging.
Biogerontology. 11:501–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krysan K, Kusko R, Grogan T, O'Hearn J,
Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, et
al: PGE2-driven expression of c-Myc and oncomiR-17-92 contributes
to apoptosis resistance in NSCLC. Mol Cancer Res. 12:765–774. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsubara H, Takeuchi T, Nishikawa E,
Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M,
Nimura Y, et al: Apoptosis induction by antisense oligonucleotides
against miR-17-5p and miR-20a in lung cancers overexpressing
miR-17-92. Oncogene. 26:6099–6105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takakura S, Mitsutake N, Nakashima M,
Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru
A and Yamashita S: Oncogenic role of miR-17-92 cluster in
anaplastic thyroid cancer cells. Cancer Sci. 99:1147–1154. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ernst A, Campos B, Meier J, Devens F,
Liesenberg F, Wolter M, Reifenberger G, Herold-Mende C, Lichter P
and Radlwimmer B: De-repression of CTGF via the miR-17-92 cluster
upon differentiation of human glioblastoma spheroid cultures.
Oncogene. 29:3411–3422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Olive V, Bennett MJ, Walker JC, Ma C,
Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ and He L: miR-19
is a key oncogenic component of mir-17-92. Genes Dev. 23:2839–2849.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uziel T, Karginov FV, Xie S, Parker JS,
Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G, et al:
The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway
in medulloblastoma. Proc Natl Acad Sci USA. 106:2812–2817. 2009.
View Article : Google Scholar
|
|
37
|
Gupta S, Read DE, Deepti A, Cawley K,
Gupta A, Oommen D, Verfaillie T, Matus S, Smith MA, Mott JL, et al:
Perk-dependent repression of miR-106b-25 cluster is required for ER
stress-induced apoptosis. Cell Death Dis. 3:e3332012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gantier MP, Stunden HJ, McCoy CE, Behlke
MA, Wang D, Kaparakis-Liaskos M, Sarvestani ST, Yang YH, Xu D, Corr
SC, et al: A miR-19 regulon that controls NF-κB signaling. Nucleic
Acids Res. 40:8048–8058. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Trenkmann M, Brock M, Gay RE, Michel BA,
Gay S and Huber LC: Tumor necrosis factor α-induced microRNA-18a
activates rheumatoid arthritis synovial fibroblasts through a
feedback loop in NF-κB signaling. Arthritis Rheum. 65:916–927.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Choi PS, Casey SC, Dill DL and
Felsher DW: MYC through miR-17-92 suppresses specific target genes
to maintain survival, autonomous proliferation, and a neoplastic
state. Cancer Cell. 26:262–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Bian C, Liao L, Li J and Zhao RC:
miR-17-5p promotes human breast cancer cell migration and invasion
through suppression of HBP1. Breast Cancer Res Treat. 126:565–575.
2011. View Article : Google Scholar
|
|
42
|
Cohen R, Greenberg E, Nemlich Y, Schachter
J and Markel G: miR-17 regulates melanoma cell motility by
inhibiting the translation of ETV1. Oncotarget. 6:19006–19016.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P,
Nie Y, Wu K, Shi Y and Fan D: MiR-19a/b modulate the metastasis of
gastric cancer cells by targeting the tumour suppressor MXD1. Cell
Death Dis. 5:e11442014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ohyagi-Hara C, Sawada K, Kamiura S, Tomita
Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T,
Takahashi T, et al: miR-92a inhibits peritoneal dissemination of
ovarian cancer cells by inhibiting integrin α5 expression. Am J
Pathol. 182:1876–1889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Barkan D and Chambers AF: β1-integrin: A
potential therapeutic target in the battle against cancer
recurrence. Clin Cancer Res. 17:7219–7223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kato H, Liao Z, Mitsios JV, Wang HY,
Deryugina EI, Varner JA, Quigley JP and Shattil SJ: The primacy
ofβ1 integrin activation in the metastatic cascade. PLoS One.
7:e465762012. View Article : Google Scholar
|
|
47
|
Lee YC, Jin JK, Cheng CJ, Huang CF, Song
JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al: Targeting
constitutively activated β1 integrins inhibits prostate cancer
metastasis. Mol Cancer Res. 11:405–417. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Somanath PR, Kandel ES, Hay N and Byzova
TV: Akt1 signaling regulates integrin activation, matrix
recognition, and fibronectin assembly. J Biol Chem.
282:22964–22976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dhar S, Gu FX, Langer R, Farokhzad OC and
Lippard SJ: Targeted delivery of cisplatin to prostate cancer cells
by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Proc Natl Acad Sci USA. 105:17356–17361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dhar S, Kolishetti N, Lippard SJ and
Farokhzad OC: Targeted delivery of a cisplatin prodrug for safer
and more effective prostate cancer therapy in vivo. Proc Natl Acad
Sci USA. 108:1850–1855. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jacobsen C and Honecker F: Cisplatin
resistance in germ cell tumours: Models and mechanisms. Andrology.
3:111–121. 2015. View Article : Google Scholar
|
|
52
|
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L,
Huang H, Li S and Zhao J: MiRNA 17 family regulates
cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
PLoS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Persons DL, Yazlovitskaya EM and Pelling
JC: Effect of extra-cellular signal-regulated kinase on p53
accumulation in response to cisplatin. J Biol Chem.
275:35778–35785. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mendoza J, Martínez J, Hernández C,
Pérez-Montiel D, Castro C, Fabián-Morales E, Santibáñez M,
González-Barrios R, Díaz-Chávez J, Andonegui MA, et al: Association
between ERCC1 and XPA expression and polymorphisms and the response
to cisplatin in testicular germ cell tumours. Br J Cancer.
109:68–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kirschner K and Melton DW: Multiple roles
of the ERCC1-XPF endonuclease in DNA repair and resistance to
anticancer drugs. Anticancer Res. 30:3223–3232. 2010.PubMed/NCBI
|
|
57
|
Li W and Melton DW: Cisplatin regulates
the MAPK kinase pathway to induce increased expression of DNA
repair gene ERCC1 and increase melanoma chemoresistance. Oncogene.
31:2412–2422. 2012. View Article : Google Scholar
|
|
58
|
Andrieux LO, Fautrel A, Bessard A,
Guillouzo A, Baffet G and Langouët S: GATA-1 is essential in
EGF-mediated induction of nucleotide excision repair activity and
ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res.
67:2114–2123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cummings M, Higginbottom K, McGurk CJ,
Wong OG, Köberle B, Oliver RT and Masters JR: XPA versus ERCC1 as
chemosensitising agents to cisplatin and mitomycin C in prostate
cancer cells: Role of ERCC1 in homologous recombination repair.
Biochem Pharmacol. 72:166–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
